Tocilizumab, sarilumab and anakinra in critically ill patients with COVID-19: a randomised, controlled, open-label, adaptive platform trial
Lennie Derde, Anthony C Gordon, Paul R Mouncey, Farah Al-Beidh, Kathryn M Rowan, Alistair D Nichol, Yaseen M Arabi, Djillali Annane, Abigail Beane, Richard Beasley, Marc J M Bonten, Charlotte A Bradbury, Frank M Brunkhorst, Adrian Buzgau, Meredith Buxton, Allen C Cheng, Nicola Cooper, Matthew Cove, Olaf L Cremer, Michelle A Detry, Eamon J Duffy, Lise J Estcourt, Mark Fitzgerald, James Galea, Herman Goossens, Rashan Haniffa, Thomas E Hills, David T Huang, Nao Ichihara, Andrew King, François Lamontagne, Patrick R Lawler, Helen L Leavis, Roger J Lewis, Edward Litton, John C Marshall, Florian B Mayr, Daniel F McAuley, Anna McGlothlin, Shay P McGuinness, Bryan J McVerry, Susan C Morpeth, Srinivas Murthy, Mihai G Netea, Kayode Ogungbenro, Katrina Orr, Rachael L Parke, Jane C Parker, Asad E Patanwala, Ville Pettila, Luis Felipe Reyes, Hiroki Saito, Marlene S Santos, Christina T Saunders, Christopher W Seymour, Manu Shankar-Hari, Wendy I Sligl, Alexis F Turgeon, Anne M Turner, Steven Y C Tong, Suvi Vaara, Taryn Youngstein, Ryan Zarychanski, Cameron Green, Alisa M Higgins, Colin J McArthur, Lindsay R Berry, Elizabeth Lorenzi, Scott Berry, Steve A Webb, Derek C Angus, Frank L van de Veerdonk
Thorax May 2025, thorax-2024-222488; DOI: 10.1136/thorax-2024-222488
